Beckman

Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Retrieved on: 
Tuesday, July 25, 2023
Beckman Coulter, Senior, CLIA, Laboratory, Beckman, Chemistry, Sigma, Small Business Saturday, FDA, AU, DXC, Medical device, Immunoassay

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry.
  • Designed for small-to-medium-sized laboratories, the DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to optimize laboratory workflows and support critical clinical decisions.
  • The DxC 500 AU Chemistry Analyzer uses standardized assays and reagents found across Beckman Coulter's portfolio of AU clinical chemistry analyzers.
  • "The Beckman Coulter DxC 500 AU Clinical Chemistry Analyzer, assessed by Six Sigma metrics, meets and/or exceeds the many demands of CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC.

Beckman Coulter Connects Scopio Labs Digital Cell Morphology with Hematology Workcell Extending Automated Workflow

Retrieved on: 
Wednesday, July 19, 2023
Beckman Coulter, Partnership, AACC, Hematology, Infection, Food and Drug Administration, Attention, Disorder, Future, Malignancy, Hospital, GM, Beckman, CBC, Anemia, Workcell, Artificial intelligence, Diagnosis, Entrepreneurship, SMS, PBS, Food, Medical device

ANAHEIM, Calif., July 19, 2023 /PRNewswire/ -- Beckman Coulter, a global leader in clinical diagnostics, today announced it will debut its hematology analyzer and slidemaker stainer connected to Scopio Labs' digital morphology platform for end-to-end digitization with artificial intelligence-assisted peripheral blood smear analysis at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo. The solution features the Beckman Coulter DxH 900 Workcell and DxH Slidemaker Stainer II connected with the Scopio X100HT digital morphology platform capable of continuous loading, scanning and analysis.

Key Points: 
  • The solution features the Beckman Coulter DxH 900 Workcell and DxH Slidemaker Stainer II connected with the Scopio X100HT digital morphology platform capable of continuous loading, scanning and analysis.
  • "With the increasing attention of hematological disorders and malignancies, the accuracy and timeliness of peripheral blood smears results are critically important for timely diagnosis and effective treatment initiation," said Dan Xu, Vice President/GM, Hematology and Urinalysis Business Units for Beckman Coulter.
  • "Connecting the Scopio X100HT with the DxH 900 Workcell is a tremendous step forward in advancing our global partnership with Beckman Coulter, which we initiated one year ago," said Itai Hayut, CEO and Co-Founder of Scopio Labs.
  • Scopio solves that trade-off, capturing large scan areas at 100X magnification, and virtually eliminates the need for additional manual microscopic examination.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics

Retrieved on: 
Monday, July 17, 2023
Biotechnology, Other Health, Health, General Health, Mental Health, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Partnership, Apolipoprotein E, Therapy, Prevalence, AFL, Disability, Public, Neurodegenerative disease, ADX, DSM-IV codes, Neurology, Biomarker, Death, Dementia, Fluid mechanics, RUO, Acquisition, Neuroscience, Patient, Laboratory, Beckman, DirectX, Blood, IVD, Immunoassay, CSF, FDA, Beckman Coulter, Disease, Medical imaging, Pharmaceutical industry, Fujirebio

The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving patients‘ health and slowing down disease progression.

Key Points: 
  • The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving patients‘ health and slowing down disease progression.
  • The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer’s Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
  • To complement the current diagnostic solutions, which rely on PET-imaging or a lumbar puncture for cerebral spinal fluid testing, Fujirebio and Beckman Coulter intend to bolster widespread access to patient-friendly, blood-based diagnostic capabilities which will complement and accelerate the impact of breakthrough Alzheimer’s Disease therapeutics.
  • We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer’s Disease care.”
    “This collaboration with Beckman Coulter will help accelerate the deployment of our portfolio of new, novel neurodegenerative biomarkers to laboratories and clinicians around the world.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test

Retrieved on: 
Monday, July 17, 2023
Beckman Coulter, Partnership, Apolipoprotein E, Therapy, Prevalence, Alzheimer's disease, AFL, Disease, Disability, Public, Neurodegenerative disease, ADX, DSM-IV codes, Research, Neurology, Biomarker, Death, Alzheimer's Disease International, Dementia, Fluid mechanics, RUO, Acquisition, Neuroscience, DirectX, Patient, Laboratory, Beckman, Blood, IVD, Immunoassay, CSF, Health, FDA, Medical imaging, Pharmaceutical industry, Fujirebio

BREA, Calif. and TOKYO, July 17, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Key Points: 
  • The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving Alzheimer's patients' health and slowing down disease progression.
  • The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer's Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
  • We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer's Disease care."
  • The availability of these new biomarkers allows clinical research professionals to further investigate clinical utility in assessing Alzheimer's Disease or other neurological disease conditions.

FS Investments Closes First FS Tactical Opportunities Fund

Retrieved on: 
Monday, May 15, 2023
Special, Martha Plimpton, Dislocation, LLP, Fund, Investment, Beckman, Security (finance), Research

PHILADELPHIA, May 15, 2023 /PRNewswire/ -- FS Investments, a leading alternative asset manager with $35 billion in assets under management, today announced the final closing of FS Tactical Opportunities Fund (the "Fund").

Key Points: 
  • PHILADELPHIA, May 15, 2023 /PRNewswire/ -- FS Investments, a leading alternative asset manager with $35 billion in assets under management, today announced the final closing of FS Tactical Opportunities Fund (the "Fund").
  • FS Tactical Opportunities Fund is a private fund intended for institutional investors.
  • The Fund originates direct investments and acquires secondary investments focused on complex, niche or unconventional situations.
  • The Fund is managed by the same seasoned FS Investments Liquid Credit & Special Situations team that manages $2.1 billion and has historically delivered strong performance for publicly traded FS Credit Opportunities Corp., which invests in capital structure solutions and secondary credit opportunities.

SCIEX collaborates with Beckman Coulter Life Sciences to bring automation to the Echo® MS system

Retrieved on: 
Monday, February 27, 2023
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, Genomics, SCIEX, Echo, Market development, Automation, SLAS, Beckman, Product management, CE, Management, Beckman Coulter

At SLAS 2023 , SCIEX , a global leader in life science analytical technologies, announces a new collaboration with Beckman Coulter Life Sciences , a global leader in laboratory workflow automation and innovation, to provide comprehensive workflows for high-throughput screening, HT-ADME and synthetic biology studies.

Key Points: 
  • At SLAS 2023 , SCIEX , a global leader in life science analytical technologies, announces a new collaboration with Beckman Coulter Life Sciences , a global leader in laboratory workflow automation and innovation, to provide comprehensive workflows for high-throughput screening, HT-ADME and synthetic biology studies.
  • The Echo® MS system , built on Acoustic Ejection Mass Spectrometry technology from SCIEX, is now compatible with the Biomek and Echo liquid handler lines from Beckman Coulter Life Sciences.
  • The Beckman Coulter Life Sciences automatic liquid handling solutions are comprised of the Echo and Biomek lines.
  • “Collaborating with the life sciences community to accelerate answers through automation and innovative solutions is what drives us every day at Beckman Coulter Life Sciences,” said Amy Yoder, Director of Product Management for Automation and Genomics at Beckman Coulter Life Sciences.

University of Louisville Hospital presents its evaluation of the Affinity Biosensor LifeScale rapid AST system at IDWeek 2022.

Retrieved on: 
Tuesday, November 8, 2022
Patient, Department, Doctor of Philosophy, Gram, Beckman, Doctor of Pharmacy, Pathology, University, Hospital, Medical laboratory, Antimicrobial stewardship, AAM, AST, Microscanning, Medical device, Medical imaging

SANTA BARBARA, Calif., Nov. 8, 2022 /PRNewswire/ -- The study, titled PERFORMANCE EVALUATION OF THE LIFESCALE AST RAPID AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY SYSTEM, assessed the performance of LifeScale compared to the Beckman Coulter MicroScan WalkAway AST System™. The study enrolled positive blood cultures from patient samples containing Gram-negative organisms. For the 1277 drug/bug combinations essential agreement was 96.50% and categorical agreement was 98.04%. There were no very major errors and only 3 major errors. Results were available in 4.5 hours and required ~8 minutes of hands-on time.

Key Points: 
  • Affinity Biosensors announces that University of Louisville Hospital completed its evaluation of the LifeScale AST rapid antibiotic susceptibility system and presented the results at IDWeek in Washington, DC
    SANTA BARBARA, Calif., Nov. 8, 2022 /PRNewswire/ -- The study, titled PERFORMANCE EVALUATION OF THE LIFESCALE AST RAPID AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY SYSTEM, assessed the performance of LifeScale compared to the Beckman Coulter MicroScan WalkAway AST System.
  • The study was led by Dr. James Snyder (Ph.D., D(ABMM), F(AAM), Professor in the Department of Pathology and Laboratory Medicine at University of Louisville Hospital.
  • The LifeScale Rapid AST Technology meets these objectives and reduces the duration of empiric therapy.
  • The system is currently under 510(k) review by the FDA and is available now for evaluation.

LION ELECTRIC APPOINTS NEW U.S. MARKETING AND TRUCK SALES EXECUTIVES, DOMINIK BECKMAN AND SYDNEY DUNN

Retrieved on: 
Tuesday, August 2, 2022
TSX, Sale, McDonnell Douglas MD-11, Lion Electric Company, Beckman, Environment, Hino Motors, NYSE, SEC, EV, Forward-looking statement, Risk, Solution, General Motors, Private Securities Litigation Reform Act, Indian stock exchange, New, Marketing, Continental, Continental AG, Nature, Multimedia, Leadership, Quality of life, Review, Company, Transport, Toronto Stock Exchange, Program, LEV, Growth, Communication, Airline, Public relations

In her new role, Dunn will oversee the medium and heavy-duty trucking sales business division in the U.S. for Lion.

Key Points: 
  • In her new role, Dunn will oversee the medium and heavy-duty trucking sales business division in the U.S. for Lion.
  • She brings two decades of sales and operations leadership experience to Lion.
  • In her most recent role as Director of Fleet Sales and Operations at ElectraMeccanica, Dunn oversaw all sales and operations for the EV manufacturer's go-to-market commercial strategy.
  • Her roles were primarily focused on the sales and marketing of conquest customers, as well as the manufacturer's re-entry into the medium-duty truck space.

Laboratory Industry Doesn't Forget COVID-19, But Shifts Focus to Other Health Conditions at AACC 2022 in Chicago

Retrieved on: 
Thursday, July 28, 2022
LRE Map, Association, Legislation, Delta-8-Tetrahydrocannabinol, Ethics, Autonomous detection system, Pediatrics, Multimedia, University of Washington Department of Bioengineering, Roche, IVD, Siemens Healthineers, Professor, Warfarin, Acquisition, Genomics, Doctor of Philosophy, Research, NASH, Cancer, AACC, University of Missouri–Kansas City School of Medicine, Mayo, Automation, AI, NAFLD, COVID-19, Liver disease, DC-1, Liver, Blood, ELF, Kidney disease, Abbott, University, Beckman, Health informatics, Thermo Fisher Scientific, Hematology, GC, Clinical professor, Risk, TLA, American Association, Approximation error, Movement, Kidney, MD, FTIR, Patient, Department, LDT, Cirrhosis, Pharmaceutical industry, Medical device, Child, Mercy, Science, Personalized medicine

CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.

Key Points: 
  • CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.
  • Kalorama Information analysts attended sessions and observed trends at the AACC meeting, noting that very little focus was related to the recent pandemic.
  • Perhaps a vestige of the COVID-19 pandemic was a focus on better and faster workflows, automation and other products.
  • AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes' trial, moderated the discussion.

Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform

Retrieved on: 
Wednesday, July 20, 2022
PBS, Diagnosis, Beckman, Laboratory, Food and Drug Administration, Degenerative disease, Food, Hematology, Hospital, CEO, Partnership, Solution, Danaher Corporation, Multimedia, Blood, BMA, Adoption, Cancer, Disorder, Review, Technology, Creativity, FDA, Disease, Time, Science, Beckman Coulter, Patient, Anemia, Workflow, Infection, AI, Medical device, Television

"It is an honor to partner with Beckman Coulter, the pioneers of automated hematology testing and a known industry innovator, to accelerate the digital transformation of hematology laboratories worldwide.

Key Points: 
  • "It is an honor to partner with Beckman Coulter, the pioneers of automated hematology testing and a known industry innovator, to accelerate the digital transformation of hematology laboratories worldwide.
  • Scopio Labs is transforming cell morphology analysis, offering a suite of fully digital applications and platforms that drastically enhance clinical workflows.
  • Solving the tradeoff between field-of-view and resolution, Scopio enables labs to assess and analyze cell morphology at unprecedented scale and depth.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.